GFP
ATNM icon

Gryphon Financial Partners’s Actinium Pharmaceuticals ATNM Stock Holding History

Gryphon Financial Partners’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-17
Closed – – 965
2017
Q4 		$0 Buy
+17
New +$342 ﹤0.01% 1012

Other funds holding ATNM

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
DAM
DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Gryphon Financial Partners's ATNM Position: Q1 2018 in Review

Gryphon Financial Partners sold out of Actinium Pharmaceuticals (ATNM) in Q1 2018, closing a stake of 17 shares.

Gryphon Financial Partners first reported a position in ATNM in Q4 2017 and held it in 1 quarter. The position peaked at $0 in Q4 2017. 36 funds tracked by Wall St. Rank hold ATNM as of Q1 2018.

  • Gryphon Financial Partners reported no remaining Actinium Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Gryphon Financial Partners sold 17 Actinium Pharmaceuticals shares in Q1 2018.
  • Gryphon Financial Partners first reported a position in Actinium Pharmaceuticals in Q4 2017 and held it in 1 quarter.
  • Gryphon Financial Partners's Actinium Pharmaceuticals position peaked at $0 in Q4 2017.
  • 36 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q1 2018.

Based on Gryphon Financial Partners's 13F filing for Q1 2018, filed 14 May 2018.